@article{JGO11921,
author = {Ilufredo Y. Tantoy and Anand Dhruva and Janine Cataldo and Alan Venook and Bruce A. Cooper and Steven M. Paul and Jon D. Levine and Yvette P. Conley and Frances Cartwright and Kathryn Lee and Fay Wright and Christine Miaskowski},
title = {Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {1},
year = {2017},
keywords = {},
abstract = {Background: Approximately 28% of patients with gastrointestinal (GI) cancers will receive targeted therapy (TT) because of the associated increases in survival. Only four studies have examined the symptom experience of these patients. To date, no studies have evaluated for differences in symptom occurrence, severity, and distress between patients who received chemotherapy (CTX) alone (n=304) or CTX with TT (n=93).
Methods: Patients completed self-report questionnaires, approximately one week after they received CTX. A modified version of the Memorial Symptom Assessment Scale (MSAS) was used to obtain data on symptom occurrence, severity, and distress. Binary logistic regression analyses were used to test for differences in symptom occurrence rates between the two treatment groups. Ordinal logistic regression analyses were used to test for differences in severity and distress ratings between the two treatment groups.
Results: Patients who received CTX with TT were significantly younger (P=0.009); were diagnosed with cancer longer (P=0.004); had a higher number of prior treatments (P=0.024); had metastatic disease, specifically to the liver (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/11921}
}